Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its leadership team will present at three upcoming industry and investor events: the 2025 Cell & Gene Meeting on the Mesa, …
Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor Conferences Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to commercialize OCU400, its experimental modifier gene …
Ocugen Strikes $7.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed an exclusive licensing agreement with South Korea’s Kwangdong Pharmaceutical Co., Ltd. for the rights to develop and commercialize OCU400, Ocugen’s experimental …
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Chairman, Chief Executive Officer, and Co-Founder Dr. Shankar Musunuri will participate in two major investor conferences this September, highlighting the company’s …
Ocugen CEO to Speak at Investor Conferences in New York and Munich Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received a key regulatory boost in its bid to bring a gene therapy for Stargardt disease to market, with the European Medicines …
Ocugen Gains EMA Backing for Single Pivotal Trial to Support Stargardt Disease Gene Therapy Approval Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it has entered into a securities purchase agreement with Janus Henderson Investors for a registered direct offering valued at approximately $20 million.
Ocugen Secures $20 Million in Direct Offering with Janus Henderson Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported its second-quarter 2025 results, showcasing clinical progress in gene therapy, new strategic partnerships, and a planned spin-off to sharpen its business focus. …
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has expanded its Retina Scientific Advisory Board (SAB) and executive leadership team as the company accelerates toward filing three Biologics License Applications (BLAs) …
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More PHILADELPHIA, PA & MALVERN, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) and OrthoCellix, Inc. have announced a definitive merger agreement to combine the two companies in an all-stock transaction. The …
Carisma Therapeutics and OrthoCellix Merge to Advance Regenerative Cell Therapy for Orthopedic Diseases Read More